Fate Therapeutics Inc (FATE)

[NY1972]

Diorio et al demonstrate that base editing enabled higher cell viability, better proliferation, and optimized CAR T-cell yields when compared with the conventional CRISPR-Cas9 nuclease system. This may be explained by reduced DNA damage response observed after quadruple editing with CBEs and better cellular fitness in the absence of gross genetic rearrangements. With overall yields between 16 × 109and 17.2 × 109 CAR+ T cells, a single manufacturing run may provide up to 200 administrations in adult patients (assuming a treatment dose of 1 × 106 CAR+ T cells per kilogram of body

https://ashpublications.org/blood/article/140/6/526/486105/The-uncut-version-base-edited-allo-CAR-T-cells